Why the study?
Do implantable left ventricular assist systems (LVAS) improve survival and quality of life in patients with advanced heart failure awaiting transplantation compared to medical therapy?
Do implantable left ventricular assist systems (LVAS) improve survival and quality of life in patients with advanced heart failure awaiting transplantation compared to medical therapy?
Implantable LVAS provide acceptable survival (60-70% at ~100 days) and dramatic improvements in quality of life for patients bridging to heart transplantation, though bleeding, thromboembolism, and infection remain important adverse events.
Answers are grounded in this paper and cite their sources.
May support LVAS as bridge to transplant in advanced HF; leaves open need for randomized comparisons to medical therapy.
Implantable left ventricular assist systems (LVAS) consist of implantable pumps with small control consoles and power sources that can be worn externally. These systems provide far greater patient mobility and independence than external pumps with bulky control consoles. Patients with implantable LVAS can be discharged from hospital and are able to return to work and resume active sports. Most patients have received these systems as a bridge to heart transplantation. Clinical status and quality of life improve dramatically after device implantation and survival on support (60-70% after approx. 100 days of support) is acceptable compared with transplant candidates on medical therapy. Patient selection and adverse events, primarily bleeding, thromboembolism and infection, are important issues with LVAS. In the future, long-term support and bridging to myocardial recovery may become important indications for LVAS.
No takes yet. Share an insight, caveat, or question.
Mohaçsi et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: